The interaction of ancrod with human platelets

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Ancrod is a serine protease used as an anticoagulant, particularly for heparin-induced thrombocytopenia.
• Ancrod cleaves fibrinogen's alpha chain, producing fibrinopeptides A, AP, and AY.
• Concerns exist regarding ancrod's direct effects on platelets, with conflicting older studies.

Purpose of the Study:

• To investigate the interaction of ancrod with human platelets.
• To determine if ancrod directly affects platelet function or surface glycoproteins.
• To clarify ancrod's safety profile in patients with heparin-induced thrombocytopenia.

Main Methods:

• Functional assays: platelet aggregation and dense-granule release.
• Biochemical analysis: glycoprotein cleavage using radioimmunoprecipitation.
• Direct binding studies with radiolabeled ancrod.

Main Results:

• Ancrod alone did not induce platelet aggregation or dense-granule release.
• Ancrod did not alter thrombin-induced platelet aggregation or serotonin release.
• High concentrations of ancrod did not cleave platelet glycoproteins Ib-IX or IIb-IIIa.
• No specific binding of ancrod to the platelet surface was observed.

Conclusions:

• Ancrod does not directly affect or bind to human platelets in vitro.
• The anticoagulant effect of ancrod is primarily due to fibrinogen depletion.
• These findings support ancrod's use in conditions like heparin-induced thrombocytopenia.